The Science · Dossier 01
A clinical reference for the mechanism, evidence, and timeline of GLP-1 induced telogen effluvium — and how Luma Root's formulation maps to it, active by active.
Every follicle on the scalp cycles independently through four phases. Telogen effluvium is a phase-distribution problem — too many follicles in resting state at once. Understanding the cycle is the first step.
Phase 01 of 04 · Growth Phase
2 – 7 years
Active hair production. Matrix cells in the follicle bulb divide rapidly, pushing the shaft upward at ~1 cm per month. Roughly 85–90% of follicles on a healthy scalp sit in this phase at any given moment.
The drug itself is not directly follicle-toxic. The problem is the rate of fat loss — a physiological stressor on the same axis as childbirth, high fever, or significant emotional trauma.
GLP-1 agonists suppress appetite-signaling pathways, producing daily deficits of 600–1,000 kcal. Sustained weight loss of 15–20% body weight is typical within six months.
Rapid fat loss elevates circulating cortisol and shifts thyroid hormone availability. Both pathways converge on the dermal papilla, where they shorten anagen and accelerate telogen entry.
Within 8–12 weeks, a large cohort of follicles transitions to resting phase simultaneously. The shed becomes visible 2–3 months later — long after the patient connected it to anything.
Most hair serums target a single pathway. Luma Root addresses telogen effluvium as a three-part problem — and the formula maps an active class to each vector.
Re-enter follicles into anagen. Redensyl signals dormant stem cells in the bulge region to resume division. Capixyl reduces DHT sensitivity at the dermal papilla.
Strengthen the follicular attachment and rebuild the keratin scaffold. Procapil tightens the dermal sheath; biotin-complex peptides reinforce shaft integrity from below.
Down-regulate the cortisol-driven stress signal that put the follicles into telogen in the first place. Ashwagandha root extract and adaptogenic botanicals work locally on the scalp.
Every compound in the Luma Root formula was selected for an existing body of peer-reviewed data. Four representative studies, summarised below — full references at the foot of this section.
INCI: Dihydroquercetin-glucoside (DHQG) + EGCG-2
Hair density vs. baseline after 84 days of 1% topical application.
Double-blind vehicle-controlled study, n=85 male subjects with androgenetic alopecia. Redensyl outperformed the 5% minoxidil reference arm in this trial on the primary endpoint of new anagen-phase follicles.
INCI: Apigenin + Oleanolic acid + Biotinyl tripeptide-1
Increase in anagen-phase follicle ratio after 4 months of daily use.
Open-label trial in subjects with mild-to-moderate alopecia. Researchers documented a measurable shift in anagen:telogen ratio and a reduction in pull-test shedding count from baseline at the 16-week endpoint.
INCI: Acetyl tetrapeptide-3 + Red clover extract
Reduction in 5α-reductase activity at the follicle (vs. control).
Mechanism studied on isolated dermal papilla cells and ex-vivo scalp biopsies. Capixyl outperformed finasteride on this specific in-vitro endpoint, suggesting topical disruption of the DHT pathway implicated in androgenetic and stress-driven thinning.
INCI: Rosmarinic acid + Carnosol
Hair count parity with 2% minoxidil at 6 months, with significantly lower scalp irritation.
Randomised controlled trial of 100 subjects directly comparing rosemary oil to topical minoxidil 2%. Both arms showed statistically significant improvement from baseline; the rosemary arm reported substantially fewer adverse scalp events.
References
Hair growth is a slow biological process. Each milestone below corresponds to a measurable shift in follicle distribution — scrub through to see what's happening, and what to expect, at each stage.
Week 3 – 4
The synchronized telogen entry begins to break up as dormant follicles signal back into anagen. Most users report measurably less hair in the shower drain — the first concrete sign the underlying biology is shifting.
Marker · Pull-test count typically halves. Density unchanged.
The patients I see on semaglutide and tirzepatide aren't going bald. They're experiencing a reversible, mechanical phase-shift in their follicle cycle. The clinical question isn't whether the hair will come back — it's how fast you can shorten the resting phase.
Start the protocol
One bottle, applied daily. A measurable change in shed within four weeks. Free shipping, 60-day satisfaction guarantee, and a dermatologist on call for every subscriber.
$68 with Subscribe & Save 20% · Cancel anytime · Ships free in 2 business days